Aristides Capital’s PTC Therapeutics PTCT Stock Holding History

Aristides Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,250	Closed	-$279K	–	160
2020 Q1	$279K	Buy	+6,250	New	+$315K	0.2%	76

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aristides Capital's PTCT Position: Q2 2020 in Review

Aristides Capital sold out of PTC Therapeutics (PTCT) in Q2 2020, closing a stake of 6,250 shares — an estimated $279K sold.

Aristides Capital first reported a position in PTCT in Q1 2020 and held it in 1 quarter. The position peaked at $279K in Q1 2020. 203 funds tracked by Wall St. Rank hold PTCT as of Q2 2020.

Aristides Capital reported no remaining PTC Therapeutics position as of Q2 2020 after selling out during the quarter.
Aristides Capital sold 6,250 PTC Therapeutics shares in Q2 2020, an estimated $279K.
Aristides Capital first reported a position in PTC Therapeutics in Q1 2020 and held it in 1 quarter.
Aristides Capital's PTC Therapeutics position peaked at $279K in Q1 2020.
203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2020.

Based on Aristides Capital's 13F filing for Q2 2020, filed 14 Aug 2020.